The Drug Enforcement Administration (DEA) is proposing a dramatic increase in its 2023 production quotas for marijuana compounds and psychedelics like psilocybin and ibogaine to “support research and clinical trials” into the substances. DEA wants to nearly double the amount of psilocybin, psilocyn and delta-9 THC that’s manufactured compared to initial levels set for this … Continue reading DEA Calls For Massive Increases In Psilocybin, Ibogaine And THC Manufacturing This Year To Meet Research Demands